ID   NCI-H1975 EGFR-D770_N771insSVD
AC   CVCL_E6DD
SY   NCI-H1975 EGFR D770_N771insSVD; H1975-insSVD
RX   PubMed=29748209;
RX   PubMed=31467113;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple_corrected; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous; Note=By TALEN (PubMed=29748209).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple_corrected; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous; Note=By TALEN (PubMed=29748209).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:3236; EGFR (Note=With p.Asp770_Asn771insSerValAsp (c.2311_2312insGCGTGGACA)).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1511 ! NCI-H1975
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=29748209; DOI=10.1158/1535-7163.MCT-17-1206;
RA   Hasako S., Terasaka M., Abe N., Uno T., Ohsawa H., Hashimoto A.,
RA   Fujita R., Tanaka K., Okayama T., Wadhwa R., Miyadera K., Aoyagi Y.,
RA   Yonekura K., Matsuo K.;
RT   "TAS6417, a novel EGFR inhibitor targeting exon 20 insertion
RT   mutations.";
RL   Mol. Cancer Ther. 17:1648-1658(2018).
//
RX   PubMed=31467113; DOI=10.1158/1541-7786.MCR-19-0419; PMCID=PMC6872223;
RA   Udagawa H., Hasako S., Ohashi A., Fujioka R., Hakozaki Y., Shibuya M.,
RA   Abe N., Komori T., Haruma T., Terasaka M., Fujita R., Hashimoto A.,
RA   Funabashi K., Yasuda H., Miyadera K., Goto K., Costa D.B.,
RA   Kobayashi S.S.;
RT   "TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase
RT   inhibitor with a broad spectrum of preclinical activity against
RT   clinically relevant EGFR mutations.";
RL   Mol. Cancer Res. 17:2233-2243(2019).
//